Europe Antibody Drug Conjugates Market Research Report - Segmented By pipeline, Technology, End User & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Size, Share, Trends, Growth, Forecast | 2024 to 2029

Updated On: June, 2024
ID: 5796
Pages: 145

Europe Antibody Drug Conjugates Market Size & Growth (2023 to 2028):

As Per the Report, the Size of the Europe Antibody Drug Conjugates Market is valued at USD 3.86 billion in 2023 and estimated to be growing at a CAGR of 25.12%, to reach USD 11.85 billion by 2028 during the forecast period 2023 to 2028.

Factors such as sedentary lifestyles and the growing number of people who smoke and drink regularly have increased the prevalence of cancer worldwide. The Europe antibody drug conjugates market is increasing owing to the increased research activity on antibody therapies, preclinical research, high research on breakthrough drug discoveries and growing demand for cost-effective and effective cancer treatments, increased research on cancerous diseases, as well as collaboration Increased between research institutes, biotechnology companies, and biopharmaceuticals industries. Antibody drug conjugates help optimize existing chemical triggers and develop new chemical triggers to generate highly selective linkers in the body. They also create novel linker-antibody couplings to produce stable and homogeneous antibody drug conjugates. In addition, they focus on improving absorption, distribution, metabolism, and excretion, which creates a favorable market outlook.

Currently, 11 FDA-approved conjugates are expected to generate more than $ 22 billion in sales per year by 2030. Due to the increasing incidence of cancer around the globe, these numbers are expected to rise. According to Globocan, cancer incidence reached 19.5 million, and the estimated cancer deaths were 9.97 million. The incidence will reach 22 million by 2025 and 26.7 million by 2030. There are around 378,000 new cancer cases in the UK every year, or 1,000 per day. The National Cancer Institute estimates that cancer diagnosis is extrapolated to approximately 15 million by 2024. Therefore, these factors could generate positive growth for the European antibody drug conjugate market during the evaluation period.

In addition, the high healthcare expenditure in European countries provides the market with an opportunity to grow during the forecast period with better treatment modalities for cancer patients in this region. Furthermore, advancements in antibody drug conjugates cross-link technology to identify and kill disease-associated cells, further stimulating the growth of ADC development in this region.

However, several factors such as the high cost of procedures and lack of funds, the lower success rate in manufacturing antibody conjugates, and strict government rules will restrain the market growth during 2020-2025. These drugs respond person to person and may not be successful in all cases, affecting patient compliance and healthcare insurance policies. Most European countries lack the required reimbursement laws for the desired cancer treatment, thus delaying the adoption of these antibody-based drug conjugates. Most cancer treatments require long-term drug usage for a better prognosis. All these factors are anticipated to reduce the growth of the European antibody drug conjugates market.

This research report on the Europe Antibody Drug Conjugates Market has been segmented and sub-segmented into the following categories 

By pipeline:

  • Phase
  • Mode of action
    • Igg1 antibodies
    • HER2 antibodies
  • Technology, linker.

By Technology:

  • Seattle genetics
  • Immunogen
  • Immunomedics

By End User:

  • Research institutes
  • Hospitals
  • Clinics

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, the Germany Antibody Drug Conjugates Market is expected to witness immense growth at a CAGR of 5.5% during the forecast period 2020-2025. The increasing incidence of cancer in the region may invite promising development. Moreover, factors such as growing awareness among the population, increasing health infrastructure, and early cancer screening initiatives will drive the market in this region.

The United Kingdom Antibody Drug Conjugates Market is expected to have the second-largest market share in the European antibody-drug conjugate market. This regional market is expected to experience substantial growth due to the increase in government initiatives and significant biopharmaceutical companies in the region.

The France Antibody Drug Conjugates Market also held a dominant share in terms of revenue in 2020, with a market share of 21.2% in the forecast period 2020-2025. This regional market is expected to show moderate growth, attributed to the availability of key players, high population growth, and increase of different types of cancers, more universities, and research centers focused on antibody and drug conjugates.

KEY MARKET PLAYERS

Prominent Companies dominating the Europe Antibody Drug Conjugates Market Profiled in the Report are Seattle Genetics, Genentech, Takeda Pharmaceuticals, F. Hoffmann-La Roche, Bayer Healthcare, Agensys, Inc., Immunogen, Novartis, Oxford Biotherapeutics, and Synthon Biopharmaceuticals.,

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample